In this issue, Huang et al. presented data from a large Taiwan cohort of 5,840 CHC patients (mean age 62.7, 33.7% cirrhotic at baseline) who achieved SVR with DAAs [13]. The patients received comprehensive SLD and CMRF workup at baseline (pre-treatment) and at six months after HCV cure. The proportion of patients with CMRFs, SLD, and metabolic-associated SLD (MASLD) at baseline were 87.8%, 36.8%, and 34.0% respectively, and these numbers were 87.4%, 37.5%, and 34.8% at six months after SVR respectively. The proportion of patients with CMRFs, SLD and MASLD remained comparable at baseline and at follow-up. Nonetheless, a dynamic shift in CMRF and SLD status was noted. Among patients with CMRFs at baseline, 3.4% had resolved CMRFs after SVR; whereas among patients without CMRFs at baseline, 20.6% had de-novo CMRF development after SVR. Among baseline MASLD patients, 27.6% became MASLD-free at follow-up; whereas 15.4% of baseline non-MASLD patients developed MASLD after SVR. Importantly, resolution of SLD after achieving SVR was more common in those without baseline CMRF than those with baseline CMRF (41.6% vs. 26.4%), with the cardiometabolic profile maintained even with resolution of SLD. These results remained robust after stratifying patients by HCV genotype (genotype 3 or other genotypes), diabetes status, body mass index (BMI) and cirrhosis status. In multivariate analysis, higher baseline BMI, glycated hemoglobin and low-density lipoprotein were the independent predictors of MASLD development respectively. In contrast, lower baseline BMI was the only factor independently associated with MASLD resolution. Other patient factors including age, sex, cirrhosis status, liver function, HCV viral load and HCV genotype were not associated with MASLD evolution after HCV cure. Overall, Huang’s study provided important data on the dynamic metabolic alterations after HCV cure.

The European Association for the Study of the Liver (EASL) published a position paper in 2024 describing post-HCV treatment care [14]. EASL recommends that patients without advanced fibrosis at baseline can be discharged to primary care, and patients with liver stiffness ≥10 kPa or FIB-4 >3.25 should continue follow-up by hepatologists. For patients with liver stiffness between 8–10 kPa or FIB-4 between 1.45–3.25, assessment of MASLD or alcohol status is required, with subsequent recommendations of lifestyle changes and reassessment by non-invasive tests. Nonetheless, the position paper highlighted that post-HCV follow-up protocols for MASLD has not been well-established. The prognostic implications of fibrosis evolution after SVR, as measured by serial non-invasive testing, is also unclear [14].

The 2024 EASL MASLD guidelines suggest that MASLD screening in the general population is not recommended, yet screening in specific high-risk populations can be considered [15]. As Huang’s study demonstrated high prevalence of CMRFs (87.8% at baseline, 87.4% at follow-up) and MASLD (34.0% at baseline, 34.8% at follow-up) in CHC patients [14], solely assessing MASLD status in CHC patients with borderline fibrosis at baseline may not suffice, and universal MASLD screening in HCV patients may be warranted. We hence propose an updated algorithm with comprehensive metabolic assessment before and after HCV cure in all CHC patients (Fig. 1).

With our proposed algorithm of metabolic assessment, we will be able to assess the dynamic shifts of CMRFs and MASLD status with HCV eradication. More importantly, we can document post-treatment CMRF and MASLD in all patients, ensuring that patients will be appropriately managed and not lost to follow-up. For patients with MASLD, smooth transition to MASLD care pathways can also be initiated. With fibrosis assessment already performed in HCV man-agement, the transition to MASLD care should be streamlined and would require minimal additional resources. While the cost-effectiveness and long-term benefits of our proposed algorithm remains to be determined, our integrated algorithm will likely improve risk stratification and enable personalization of follow-up after HCV cure.

With enhanced efforts in HCV eradication and the growing obesity pandemic, the number of patients with MASLD after HCV eradication is anticipated to increase. The paper by Huang et al. provided important data on the dynamic shift of MASLD status after HCV cure. Furthermore, the paper highlighted that CMRFs remain as the key drivers of MASLD resolution and development respectively. CMRFs and MASLD should not be overlooked in CHC, and actions must be taken to improve patient care pathways after HCV cure.